Pharmakopsychiatrie, Neuro-Psychopharmakologie
September 1, 1976
P Bickel, A Dittrich, J Schoepf
12 citations
A controlled study on 38 volunteers assessed the effects of 250 mcg/kg DMT injected intramuscularly, with 26 receiving the drug and 12 receiving a placebo. Despite the low dose compared to earlier studies, significant differences from placebo emerged across multiple syndromes of altered consciousness: visual hallucinations or illusions, impaired memory and attention, changes in body image, depersonalization, derealization, euphoria, an anxious-depressive state, and delusion. Somatic side effects included subjective respiratory troubles, dizziness, and weakness.
Archiv fur Psychiatrie und Nervenkrankheiten
December 31, 1976
A Dittrich, P Bickel, J Schöpf et al.
8 citations
Two hallucinogens, delta9-THC (the main psychoactive component of cannabis) and DMT (a powerful psychedelic), produce very similar subjective effects. In a controlled experiment, 24 subjects received oral delta9-THC and 26 received injected DMT, each at 250 micrograms per kilogram of body weight, with 24 subjects receiving a placebo. Both hallucinogens significantly altered consciousness across eight measured scales—including visual and auditory hallucinations, memory impairment, depersonalization, and euphoria—compared to placebo. However, no significant differences were found between the two drugs on any scale, though DMT showed a tendency toward stronger visual effects. The study discusses methodological challenges in comparing different hallucinogens.